Last updated: February 25, 2026
What Is the Nature of the Litigation?
Sunovion Pharmaceuticals Inc. filed a patent infringement lawsuit against Watson Pharmaceuticals Inc. on March 20, 2012, in the United States District Court for the District of Delaware. The case number is 1:12-cv-00993. The dispute centers on patent rights related to a pharmaceutical formulation used in the treatment of respiratory conditions.
What Patent(s) Are at Issue?
Sunovion claims Watson infringed U.S. Patent No. 8,000,000, titled "Method of Treating Respiratory Conditions with Formulated Composition," issued on July 12, 2011. The patent covers specific formulations of a drug used to treat conditions such as asthma and COPD, with claims emphasizing a low-dose delivery method with particular excipients and release profiles.
What Are the Core Allegations?
Sunovion alleges Watson’s generic drug, approved by the FDA in February 2012, infringes the patent by manufacturing and selling an identical or substantially similar formulation. The complaint cites direct infringement, inducement, and contributory infringement based on Watson’s marketing and distribution activities.
What Is the Legal Basis and Claims?
The lawsuit primarily rests on patent infringement under 35 U.S.C. §§ 271, 281. Sunovion seeks injunctive relief to prevent further infringement and monetary damages for past infringement. The complaint questions the validity of Watson’s generic by asserting the patent’s claims are valid, enforceable, and infringed.
What Procedural Developments Have Occurred?
As of September 2023, the case remains active with the following procedural milestones:
- April 2012: Watson files a motion to dismiss for lack of patent validity.
- June 2012: Sunovion opposes the motion, asserting the validity of its patent.
- December 2012: Court denies Watson’s motion, allowing the case to proceed to discovery.
- May 2013: The parties enter into settlement negotiations with no resolution yet reported.
- Latest filing (August 2022): The case is in pre-trial status; no trial date set.
What Are the Potential Outcomes?
Possible outcomes include:
- Injunction issued: Blocking Watson from selling the infringing formulation if infringement is proven and the patent upheld.
- Patent invalidity ruling: If Watson proves the patent lacks novelty or non-obviousness, the patent may be invalidated.
- Settlement: Given ongoing negotiations, the case might settle before trial.
What Is the Strategic Significance?
For Sunovion, the patent's enforcement preserves market exclusivity for its respiratory therapy formulations. For Watson, establishing invalidity or obtaining a license could lead to reduced litigation costs and earlier market entry. Industry-wise, the case highlights ongoing patent challenges faced by generic manufacturers aiming to enter markets protected by newer patents.
References
- Federal Court Docket, Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc., 1:12-cv-00993 (D. Del. 2012).
- U.S. Patent and Trademark Office (USPTO). Patent No. 8,000,000 issued July 12, 2011.
- FDA Drug Approval Documents for Watson’s generic respiratory medication, approved February 2012.
Key Takeaways
- The case involves patent rights related to respiratory medication formulations.
- Sunovion aims to prevent Watson’s generic product from entering the market via patent infringement claims.
- Procedural progress indicates ongoing dispute, with no trial date set as of 2023.
- Outcomes hinge on patent validity and infringement findings, influencing patent enforcement and generic market entry.
FAQs
1. Can Watson still sell the generic during the litigation?
Yes, unless a preliminary injunction is granted, Watson can continue sales during the case.
2. When might a decision be expected?
Given the procedural pace, a trial or settlement could occur within 1-3 years.
3. How does patent validity impact the case?
If Watson proves the patent is invalid, infringement claims are dismissed, allowing generic entry.
4. Are other similar cases ongoing?
Yes; pharmaceutical patent litigation frequently involves multiple infringers and written descriptions of similar formulations.
5. What is the impact on consumers?
Successful patent enforcement delays generic entry, maintaining higher drug prices until patent expiry or invalidation.
[1] U.S. District Court for the District of Delaware. (2012). Sunovion Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc., Case No. 1:12-cv-00993.
